Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1981 Jan;34(1):63–68. doi: 10.1136/jcp.34.1.63

Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time.

A D Heyns, D J van den Berg, P H Kleynhans, P W du Toit
PMCID: PMC1146412  PMID: 7462439

Abstract

Activated partial thromboplastin times (APTT) for monitoring heparin therapy for venous thromboembolism tended to be inappropriately short if blood was collected in commercially available evacuated glass tubes. Five types of evacuated tubes marketed under the trade names Vacutainer and Venoject were examined. The APTT of heparinized blood collected in these tubes correlated poorly (r = 0.04 to 4 = 0.25) with that of blood samples from the same patients collected in plastic tubes. Most of the evacuated tube APTT were shorter than that of blood collected in plastic or siliconised glass tubes, but the results were unpredictable and varied from tube to tube and from batch to batch. This effect on heparin is apparently due to an unidentified substances which is eluted from the rubber stoppers of the tubes. Heparin control according to the APTT blood collected in these evacuated tubes is hazardous.

Full text

PDF
63

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babson A. L., Babson S. R. Comparative evaluation of a partial thromboplastin reagent containing a non-settling, particulate activator. Am J Clin Pathol. 1974 Dec;62(6):856–860. doi: 10.1093/ajcp/62.6.856. [DOI] [PubMed] [Google Scholar]
  2. Basu D., Gallus A., Hirsh J., Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972 Aug 17;287(7):324–327. doi: 10.1056/NEJM197208172870703. [DOI] [PubMed] [Google Scholar]
  3. Blackburn E. K., Shinton N. K. Blood specimen collection tubes for coagulation tests. Br Med J. 1979 Mar 31;1(6167):894–895. doi: 10.1136/bmj.1.6167.894-c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cotham R. H., Shand D. Spuriously low plasma propranolol concentrations resulting from blood collection methods. Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):535–538. doi: 10.1002/cpt1975185part1535. [DOI] [PubMed] [Google Scholar]
  5. Fremstad D., Bergerud K. Letter: Reduced binding of quinidine in plasma from Vacutainers. Clin Pharmacol Ther. 1976 Jul;20(1):120–120. doi: 10.1002/cpt1976201120. [DOI] [PubMed] [Google Scholar]
  6. Fremstad D., Bergerud K. Plasma protein binding of drugs as influenced by blood collection methods. Acta Pharmacol Toxicol (Copenh) 1976;39(5):570–572. doi: 10.1111/j.1600-0773.1976.tb03207.x. [DOI] [PubMed] [Google Scholar]
  7. Houbouyan L. L., Roussi J. H., Goguel A. F. Effet anti-héparine dans les tubes "B.D. Vacutainer". Nouv Presse Med. 1978 Oct 21;7(36):3262–3262. [PubMed] [Google Scholar]
  8. Jick H., Slone D., Borda I. T., Shapiro S. Efficacy and toxicity of heparin in relation to age and sex. N Engl J Med. 1968 Aug 8;279(6):284–286. doi: 10.1056/NEJM196808082790603. [DOI] [PubMed] [Google Scholar]
  9. Kernohan R. J., Todd C. Heparin therapy in thromboembolic disease. Lancet. 1966 Mar 19;1(7438):621–623. doi: 10.1016/s0140-6736(66)90822-1. [DOI] [PubMed] [Google Scholar]
  10. Kessler K. M., Leech R. C., Spann J. F. Blood collection techniques, heparin and quinidine protein binding. Clin Pharmacol Ther. 1979 Feb;25(2):204–210. doi: 10.1002/cpt1979252204. [DOI] [PubMed] [Google Scholar]
  11. Nackowski S. B., Putnam R. D., Robbins D. A., Varner M. O., White L. D., Nelson K. W. Trace metal contamination of evacuated blood collection tubes. Am Ind Hyg Assoc J. 1977 Oct;38(10):503–508. doi: 10.1080/0002889778507664. [DOI] [PubMed] [Google Scholar]
  12. Norén I., Blombäck M., Fridell E., Wallinder U. Vacutainer sampling for blood coagulation assays. Scand J Clin Lab Invest. 1978 Feb;38(1):63–68. doi: 10.3109/00365517809108404. [DOI] [PubMed] [Google Scholar]
  13. O'Sullivan E. F., Hirsh J., McCarthy R. A., de Gruchy G. C. Heparin in the treatment of venous thrombo-embolic disease: administration, control and results. Med J Aust. 1968 Jul 27;2(4):153–159. doi: 10.5694/j.1326-5377.1968.tb29378.x. [DOI] [PubMed] [Google Scholar]
  14. Piafsky K. M., Borga O. Inhibitor of drug-protein binding in "Vacutainers". Lancet. 1976 Oct 30;2(7992):963–964. doi: 10.1016/s0140-6736(76)90927-2. [DOI] [PubMed] [Google Scholar]
  15. Pitney W. R., Pettit J. E., Armstrong L. Control of heparin therapy. Br Med J. 1970 Oct 17;4(5728):139–141. doi: 10.1136/bmj.4.5728.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. STRUVER G. P., BITTNER D. L. The partial thromboplastin time (cephalin time) in anticoagulation therapy. Am J Clin Pathol. 1962 Nov;38:473–481. doi: 10.1093/ajcp/38.5.473. [DOI] [PubMed] [Google Scholar]
  17. Soloway H. B., Cox S. P., Donahoo J. V. Sensitivity of the activated partial thromboplastin time to heparin: effect of anticoagulant used for sample collection. Am J Clin Pathol. 1973 May;59(5):760–762. doi: 10.1093/ajcp/59.5.760. [DOI] [PubMed] [Google Scholar]
  18. Zucker S., Cathey M. H. Control of heparin therapy. Sensitivity of the activated partial thromboplastin time for monitoring the antithrombotic effects of heparin. J Lab Clin Med. 1969 Feb;73(2):320–326. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES